Author + information
- Received July 30, 2019
- Revision received November 4, 2019
- Accepted November 5, 2019
- Published online January 6, 2020.
- Juan Guido Chiabrando, MDa,b,∗,
- Aldo Bonaventura, MDa,c,∗,
- Alessandra Vecchié, MDa,c,
- George F. Wohlford, PharmDd,
- Adolfo G. Mauro, PhDa,
- Jennifer H. Jordan, PhDa,e,
- John D. Grizzard, MDf,
- Fabrizio Montecucco, MD, PhDc,g,
- Daniel Horacio Berrocal, MD, PhDb,
- Antonio Brucato, MDh,
- Massimo Imazio, MDi and
- Antonio Abbate, MD, PhDa,∗ (, )@VCUHealth@AbbateAntonio
- aVCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia
- bDepartment of Cardiology, Hospital Italiano, Buenos Aires, Argentina
- cFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy
- dVCU School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia
- eDepartment of Biomedical Engineering, Virginia Commonwealth University, Richmond, Virginia
- fDepartment of Radiology, Virginia Commonwealth University, Richmond, Virginia
- gIRCCS Ospedale Policlinico San Martino Genova–Italian Cardiovascular Network, Genoa, Italy
- hDepartment of Biomedical and Clinical Sciences “Sacco,” University of Milano, Ospedale Fatebenefratelli, Milan, Italy
- iUniversity Cardiology, AOU Città della Salute e della Scienza di Torino, Turin, Italy
- ↵∗Address for correspondence:
Dr. Antonio Abbate, VCU Pauley Heart Center, Department of Internal Medicine, Division of Cardiology, 1200 East Broad Street, West Hospital, West wing 5-020, P.O. Box 980204, Richmond, Virginia 23298.
• Pericarditis is the most common disease of the pericardium. Generally self-limiting, pericarditis can be fraught by a significant risk of acute complications and of recurrences.
• Prompt diagnosis and appropriate treatment of acute pericarditis may reduce the risk of acute complications and recurrences.
• New therapies, such as IL-1 blockers, show promising results in patients with recurrent/refractory pericarditis.
• Future studies are needed to deepen the knowledge about pericarditis pathophysiology and provide targeted therapies.
Pericarditis refers to the inflammation of the pericardial layers, resulting from a variety of stimuli triggering a stereotyped immune response, and characterized by chest pain associated often with peculiar electrocardiographic changes and, at times, accompanied by pericardial effusion. Acute pericarditis is generally self-limited and not life-threatening; yet, it may cause significant short-term disability, be complicated by either a large pericardial effusion or tamponade, and carry a significant risk of recurrence. The mainstay of treatment of pericarditis is represented by anti-inflammatory drugs. Anti-inflammatory treatments vary, however, in both effectiveness and side-effect profile. The objective of this review is to summarize the up-to-date management of acute and recurrent pericarditis.
↵∗ Drs. Chiabrando and Bonaventura contributed equally to this work.
Drs. Brucato and Imazio have received research support from and have served as advisors to Swedish Orphan Biovitrum and Acarpia. Dr. Abbate has received research support from and has served as an advisor to Swedish Orphan Biovitrum, Kiniksa, and Olatec. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received July 30, 2019.
- Revision received November 4, 2019.
- Accepted November 5, 2019.
- 2020 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.